Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

CERo Therapeutics Holdings, Inc. has announced that the Sarah Cannon Research Institute at the Colorado Blood Cancer Institute will be a key clinical trial site for its Phase 1 trial of CER-1236 ...

Holdings announces that Sarah Cannon Research Institute, SCRI, at Colorado Blood Cancer Institute, CBCI, in Denver, ...

Y-mAbs Therapeutics (YMAB) announced that the first patient has been administered both the first protein dose and the Lu-DOTA imaging dose in ...

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.“I’ve argued for a long time that for phase 1 ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors. A phase 2a clinical trial of NEO100-01 is continuing ...

Bicara Therapeutics Inc. announced that new data from their ongoing Phase 1/1b clinical trial of ficerafusp alfa, a first-in-class bifunctional antibody, will be presented orally at the 2025 ASCO ...

April 22, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical ... follow-up in the KT-621 Phase 1 healthy volunteer trial with data to be reported ...

The presentation will report updated clinical and translational findings from the ongoing Phase 1/2 trial (STARt-001) evaluating invikafusp alfa (STAR0602) in patients with anti-PD(L)1-resistant ...

MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company ...

The Phase 1 clinical trial, currently taking place in Australia, is designed to evaluate the safety, tolerability, and preliminary efficacy of AP402 in HER2+ patients with advanced solid tumors ...